Fig. 3: Ex vivo suppression of eicosanoid production by GK420. | Nature Communications

Fig. 3: Ex vivo suppression of eicosanoid production by GK420.

From: Next generation thiazolyl ketone inhibitors of cytosolic phospholipase A2 α for targeted cancer therapy

Fig. 3

a Eicosanoid levels (pmol/mL) in the plasma of whole blood pretreated with vehicle (DMSO), 3, 10 or 30 µM GK420,) 10 µM arachidonyl trifluoromethyl ketone (ATK), or 1 μM indomethacin (Indo)  before stimulation with 1 µg/mL LPS for 24 h. In AA + LPS, 5 µM AA was included for the final 30 min. b Eicosanoid levels (pg/mL) in the supernatants of isolated human PBMCs pretreated with vehicle (DMSO), GK420, naproxen, celecoxib, or nordihydroguaiaretic acid (NDGA) for 90 min before stimulation with 30 μM A23187 for 15 min. All box and whisker plots show the mean (center line), stdev (box), and min and max values (whiskers) from 4 biological replicates. P-values were determined using RM-one way ANOVA with Dunnett’s correction for multiple comparisons.

Back to article page